Skip to main content
. 2022 May 10;29(11):2247–2261. doi: 10.1038/s41418-022-01012-0

Fig. 8. RBMS1 depletion enhances anti-tumor activity of B7-H3.CAR-T cells targeting human TNBC.

Fig. 8

A Schematic of CAR-T therapy in breast cancer. B, C MDA-MB-231 cells with stable depletion of RBMS1 or control co-cultured with B7H3-specific CAR-T cells (n = 4). CD7+ CD276dim cells were gated as CAR-T cells while CD7− CD276hi cells were gated as tumor cells. Representative flow cytometry plot (B) and quantification of residual tumor cells (C) are illustrated. Numbers in panel I indicate absolute count of tumor cells. As control, we used tumor cells without T cells (Untreated). *P < 0.05. D Schematic of how RBMS1 regulates the level of PD-L1 through B4GALT1 and modulates anti-tumor T cell immunity in TNBC.